JP2019503386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503386A5 JP2019503386A5 JP2018539087A JP2018539087A JP2019503386A5 JP 2019503386 A5 JP2019503386 A5 JP 2019503386A5 JP 2018539087 A JP2018539087 A JP 2018539087A JP 2018539087 A JP2018539087 A JP 2018539087A JP 2019503386 A5 JP2019503386 A5 JP 2019503386A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- inhibitor
- entinostat
- administered
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288121P | 2016-01-28 | 2016-01-28 | |
| US62/288,121 | 2016-01-28 | ||
| PCT/US2017/015389 WO2017132536A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019503386A JP2019503386A (ja) | 2019-02-07 |
| JP2019503386A5 true JP2019503386A5 (https=) | 2020-03-05 |
Family
ID=58010402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539087A Pending JP2019503386A (ja) | 2016-01-28 | 2017-01-27 | 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10813919B2 (https=) |
| EP (1) | EP3407913A1 (https=) |
| JP (1) | JP2019503386A (https=) |
| KR (1) | KR20180104122A (https=) |
| CN (1) | CN108883179A (https=) |
| AU (1) | AU2017211383A1 (https=) |
| BR (1) | BR112018015291A2 (https=) |
| CA (1) | CA3013047A1 (https=) |
| IL (1) | IL260765A (https=) |
| MX (1) | MX2018009247A (https=) |
| RU (1) | RU2018130831A (https=) |
| WO (1) | WO2017132536A1 (https=) |
| ZA (1) | ZA201805066B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| CA3066053A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| WO2019140296A1 (en) * | 2018-01-12 | 2019-07-18 | Viracta Therapeutics, Inc. | Epigenetic modifiers for use in cellular immunotherapy |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| CN112569360A (zh) * | 2019-09-30 | 2021-03-30 | 中国医学科学院药物研究所 | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 |
| CA3227993A1 (en) | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
| WO2024231293A1 (en) * | 2023-05-05 | 2024-11-14 | Euro-Celtique S.A. | Combinations for treating cancer |
| US20240382463A1 (en) * | 2023-05-18 | 2024-11-21 | Avstera Therapeutics Corp. | Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same |
| US12553903B2 (en) | 2023-06-01 | 2026-02-17 | Cg Pharmaceuticals, Inc | Ivaltinostat combination therapy for treating pancreatic cancer |
| WO2025155922A1 (en) * | 2024-01-19 | 2025-07-24 | The Trustees Of Indiana University | Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| JP2018508593A (ja) * | 2015-03-20 | 2018-03-29 | シンダックス ファーマシューティカルズ，インコーポレイティド | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ |
| US20180250320A1 (en) | 2015-08-26 | 2018-09-06 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| AU2016318136B2 (en) * | 2015-09-02 | 2022-10-20 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
-
2017
- 2017-01-27 RU RU2018130831A patent/RU2018130831A/ru not_active Application Discontinuation
- 2017-01-27 BR BR112018015291A patent/BR112018015291A2/pt not_active IP Right Cessation
- 2017-01-27 AU AU2017211383A patent/AU2017211383A1/en not_active Abandoned
- 2017-01-27 KR KR1020187024674A patent/KR20180104122A/ko not_active Withdrawn
- 2017-01-27 EP EP17704370.0A patent/EP3407913A1/en not_active Withdrawn
- 2017-01-27 WO PCT/US2017/015389 patent/WO2017132536A1/en not_active Ceased
- 2017-01-27 US US16/072,659 patent/US10813919B2/en active Active
- 2017-01-27 CN CN201780020460.2A patent/CN108883179A/zh active Pending
- 2017-01-27 JP JP2018539087A patent/JP2019503386A/ja active Pending
- 2017-01-27 MX MX2018009247A patent/MX2018009247A/es unknown
- 2017-01-27 CA CA3013047A patent/CA3013047A1/en not_active Abandoned
-
2018
- 2018-07-24 IL IL260765A patent/IL260765A/en unknown
- 2018-07-27 ZA ZA2018/05066A patent/ZA201805066B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503386A5 (https=) | ||
| RU2018130831A (ru) | Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии | |
| US20240390375A1 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| RU2012135396A (ru) | Способы лечения рака с применением ингибитора аутофагии на основе тиоксантона | |
| US20240041848A1 (en) | Methods and compositions for treating herpesvirus induced conditions | |
| JP2021038228A5 (https=) | ||
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| Demonté et al. | Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies | |
| Wada et al. | α-Keto amides as inhibitors of histone deacetylase | |
| AU2006212772B2 (en) | Combination of organic compounds | |
| JP2009539862A5 (https=) | ||
| JP2011516565A5 (https=) | ||
| UA81499C2 (en) | Pharmaceutical composition containing histone deacetylase inhibitor | |
| JPWO2004017996A1 (ja) | 関節軟骨細胞外マトリクス分解阻害剤 | |
| JP2009521424A (ja) | 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤 | |
| HUP0100998A2 (hu) | (2E)-5-amino-5-metil-hex-2-én-sav-N-metil-N-{(1R)-1-[N-metil-N-/(1R)-1-(metil-karbamoil)-2-fenil-etil/-karbamoil]-2-(2-naftil)-etil}-amid-sók, eljárás azok előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| RU2016136193A (ru) | Аминокарбонилкарбаматные соединения | |
| BRPI0609915A2 (pt) | métodos para tratar aterosclerose | |
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
| AU2006311723A1 (en) | Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent | |
| EA202190077A1 (ru) | Ингибиторы гистондеацетилазы | |
| EA201101305A1 (ru) | Лечение рака поджелудочной железы | |
| EP1458378A1 (en) | Amino acid derivatives useful for the treatment of alzheimer's disease | |
| HRP20110370T1 (hr) | Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma |